NASDAQ:ZBIO 22 December 2025

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma shares dropped 5.8% to $15.66 in premarket trading Tuesday, extending a 52% plunge after Phase 3 data for obexelimab in IgG4-related disease. The drug met its main goal but fell short of results seen with Amgen’s Uplizna, prompting Morgan Stanley to downgrade the stock and cut its price target. Zenas plans to file for FDA approval in Q2 2026.

6 January 2026

NASDAQ:ZBIO·Pharmaceutical News·Stock Market

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma shares dropped 5.2% to $37.03 in afternoon trading Tuesday, with about 123,000 shares changing hands. The decline followed broader weakness in biotech stocks and muted trading ahead of Federal Reserve minutes. The stock ranged from $36.94 to $40.50. No new company-specific news was reported.

30 December 2025

NASDAQ:RPRX·NASDAQ:ZBIO·Stock Market

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma shares were unchanged at $39.05 in premarket trading Tuesday after falling 8.1% Monday. The stock is down about 12% from its December 24 high as investors await Phase 3 INDIGO trial results expected around year-end. Monday’s session saw shares dip to $38.96 before closing at $39.05. Technical support is near $37.78, with resistance just above $41.

30 December 2025

NASDAQ:ZBIO·Stock Market

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma shares jumped about 14% to $41.23 on December 22, 2025, hitting a record high of $41.67 ahead of expected Phase 3 INDIGO trial results for obexelimab in IgG4-related disease. Citi and Wedbush both reiterated bullish ratings and price targets, citing the upcoming clinical data as a near-term catalyst.

22 December 2025

Financial Forecasts·NASDAQ:ZBIO

Nvidia AI Stock Shows Potential for Generational Wealth in Expanding Market
March 20, 2026, 4:08 AM EDT. Nvidia, a leader in artificial intelligence (AI) chips, ended fiscal 2026 with $216 billion in revenue, up 65% year-over-year. The company expects $78 billion in revenue for the next quarter, marking a 77% increase. Nvidia dominates the AI chip market with a 90% share, in a sector projected to grow from $500 billion in 2026 to $1 trillion by 2030. Growth in AI-powered physical applications-robots, drones, autonomous vehicles-added $6 billion in revenue. Analysts see Nvidia's strong positioning in the rapidly expanding AI market as a driver for sustained growth and potential generational wealth for investors.